Clinical features as predictors of overall survival in patients with diffuse large B-cell lymphoma with TP53 mutations in the DNA and non–DNA-binding domains
| Clinical features . | Mutated TP53, n (%) (n = 102) . | DNA-binding domain mutations, n (%) (n = 62) . | HR* . | 95% CI . | P† . | Non–DNA-binding domain mutations, n (%) (n = 40) . | HR* . | 95% CI . | P† . |
|---|---|---|---|---|---|---|---|---|---|
| Sex | |||||||||
| Male | 35 (55) | 24 (57) | 1.2 | 0.6-2.6 | 0.570 | 11 (50) | 1.2 | 0.4-3.7 | 0.712 |
| Female | 29 (45) | 18 (43) | 11 (50) | ||||||
| Age at diagnosis | |||||||||
| Younger than 60 y | 39 (62) | 26 (63) | 0.6 | 0.3-1.3 | 0.210 | 13 (59) | 0.4 | 0.1-1.1 | 0.084 |
| At least 60 y | 24 (38) | 15 (37) | 9 (41) | ||||||
| Stage | |||||||||
| I/II | 33 (52) | 19 (46) | 0.8 | 0.4-1.6 | 0.448 | 14 (64) | 0.7 | 0.2-2.2 | 0.597 |
| III/IV | 30 (48) | 22 (54) | 8 (36) | ||||||
| B symptoms | |||||||||
| No | 29 (63) | 18 (64) | 1.1 | 0.4-2.6 | 0.900 | 11 (61) | 1.1 | 0.3-3.6 | 0.901 |
| Yes | 17 (37) | 10 (36) | 7 (39) | ||||||
| No. of extranodal sites | |||||||||
| Fewer than 2 | 51 (84) | 35 (88) | 0.5 | 0.2-1.4 | 0.174 | 16 (76) | 1.1 | 0.3-4.0 | 0.890 |
| At least 2 | 10 (16) | 5 (13) | 5 (24) | ||||||
| Serum LDH level | |||||||||
| Normal | 12 (20) | 8 (21) | 0.2 | 0.1-0.7 | 0.210 | 4 (19) | 0.7 | 0.1-3.1 | 0.597 |
| Elevated | 47 (80) | 30 (79) | 17 (81) | ||||||
| Performance score | |||||||||
| Low | 14 (31) | 8 (30) | 0.6 | 0.2-1.6 | 0.285 | 6 (33) | 0.7 | 0.2-2.3 | 0.507 |
| High | 31 (69) | 19 (70) | 12 (67) | ||||||
| Size of largest tumor mass | |||||||||
| Less than 10 cm | 36 (64) | 21 (60) | 1.0 | 0.5-2.4 | 0.918 | 15 (71) | 0.3 | 0.1-1.0 | 0.057 |
| At least 10 cm | 20 (36) | 14 (40) | 6 (29) | ||||||
| IPI risk group | |||||||||
| Low (0-2) | 45 (78) | 30 (79) | 0.3 | 0.1-0.9 | 0.026 | 15 (75) | 0.9 | 0.2-3.3 | 0.838 |
| High (3-5) | 13 (22) | 8 (21) | 5 (25) | ||||||
| Initial chemotherapy | |||||||||
| CHOP/CHOP-like | 73 (91) | 44 (90) | 0.9 | 0.3-2.5 | 0.825 | 29 (94) | 1.4 | 0.3-6.3 | 0.677 |
| Other | 7 (9) | 5 (10) | 2 (6) | ||||||
| Initial radiation therapy | |||||||||
| None | 69 (86) | 41 (82) | 1.7 | 0.7-4.4 | 0.271 | 28 (93) | 0.5 | 0.1-2.3 | 0.403 |
| Involved/extended field | 11 (14) | 9 (18) | 2 (7) | ||||||
| Treatment response | |||||||||
| Complete remission | 34 (57) | 21 (54) | 0.2 | 0.1-0.5 | 0.001 | 13 (62) | 0.2 | 0.1-0.7 | 0.014 |
| Partial response | 10 (17) | 8 (21) | 2 (10) | ||||||
| No response | 6 (10) | 2 (5) | 4 (19) | ||||||
| Progressive disease | 10 (17) | 8 (21) | 2 (10) | ||||||
| Clinical features . | Mutated TP53, n (%) (n = 102) . | DNA-binding domain mutations, n (%) (n = 62) . | HR* . | 95% CI . | P† . | Non–DNA-binding domain mutations, n (%) (n = 40) . | HR* . | 95% CI . | P† . |
|---|---|---|---|---|---|---|---|---|---|
| Sex | |||||||||
| Male | 35 (55) | 24 (57) | 1.2 | 0.6-2.6 | 0.570 | 11 (50) | 1.2 | 0.4-3.7 | 0.712 |
| Female | 29 (45) | 18 (43) | 11 (50) | ||||||
| Age at diagnosis | |||||||||
| Younger than 60 y | 39 (62) | 26 (63) | 0.6 | 0.3-1.3 | 0.210 | 13 (59) | 0.4 | 0.1-1.1 | 0.084 |
| At least 60 y | 24 (38) | 15 (37) | 9 (41) | ||||||
| Stage | |||||||||
| I/II | 33 (52) | 19 (46) | 0.8 | 0.4-1.6 | 0.448 | 14 (64) | 0.7 | 0.2-2.2 | 0.597 |
| III/IV | 30 (48) | 22 (54) | 8 (36) | ||||||
| B symptoms | |||||||||
| No | 29 (63) | 18 (64) | 1.1 | 0.4-2.6 | 0.900 | 11 (61) | 1.1 | 0.3-3.6 | 0.901 |
| Yes | 17 (37) | 10 (36) | 7 (39) | ||||||
| No. of extranodal sites | |||||||||
| Fewer than 2 | 51 (84) | 35 (88) | 0.5 | 0.2-1.4 | 0.174 | 16 (76) | 1.1 | 0.3-4.0 | 0.890 |
| At least 2 | 10 (16) | 5 (13) | 5 (24) | ||||||
| Serum LDH level | |||||||||
| Normal | 12 (20) | 8 (21) | 0.2 | 0.1-0.7 | 0.210 | 4 (19) | 0.7 | 0.1-3.1 | 0.597 |
| Elevated | 47 (80) | 30 (79) | 17 (81) | ||||||
| Performance score | |||||||||
| Low | 14 (31) | 8 (30) | 0.6 | 0.2-1.6 | 0.285 | 6 (33) | 0.7 | 0.2-2.3 | 0.507 |
| High | 31 (69) | 19 (70) | 12 (67) | ||||||
| Size of largest tumor mass | |||||||||
| Less than 10 cm | 36 (64) | 21 (60) | 1.0 | 0.5-2.4 | 0.918 | 15 (71) | 0.3 | 0.1-1.0 | 0.057 |
| At least 10 cm | 20 (36) | 14 (40) | 6 (29) | ||||||
| IPI risk group | |||||||||
| Low (0-2) | 45 (78) | 30 (79) | 0.3 | 0.1-0.9 | 0.026 | 15 (75) | 0.9 | 0.2-3.3 | 0.838 |
| High (3-5) | 13 (22) | 8 (21) | 5 (25) | ||||||
| Initial chemotherapy | |||||||||
| CHOP/CHOP-like | 73 (91) | 44 (90) | 0.9 | 0.3-2.5 | 0.825 | 29 (94) | 1.4 | 0.3-6.3 | 0.677 |
| Other | 7 (9) | 5 (10) | 2 (6) | ||||||
| Initial radiation therapy | |||||||||
| None | 69 (86) | 41 (82) | 1.7 | 0.7-4.4 | 0.271 | 28 (93) | 0.5 | 0.1-2.3 | 0.403 |
| Involved/extended field | 11 (14) | 9 (18) | 2 (7) | ||||||
| Treatment response | |||||||||
| Complete remission | 34 (57) | 21 (54) | 0.2 | 0.1-0.5 | 0.001 | 13 (62) | 0.2 | 0.1-0.7 | 0.014 |
| Partial response | 10 (17) | 8 (21) | 2 (10) | ||||||
| No response | 6 (10) | 2 (5) | 4 (19) | ||||||
| Progressive disease | 10 (17) | 8 (21) | 2 (10) | ||||||